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Abstract
Background: Diabetes and neurological disorders are a growing burden among the elderly, and may also make
them more susceptible to particulate air matter with aerodynamic diameter less than 2.5 μg (PM2.5). The same
biological responses thought to effect cardiovascular disease through air pollution-mediated systemic oxidative
stress, inflammation and cerebrovascular dysfunction could also be relevant for diabetes and neurodegenerative
diseases.
Methods: We conducted multi-site case-crossover analyses of all-cause deaths and of hospitalizations for diabetes
or neurological disorders among Medicare enrollees (>65 years) during the period 1999 to 2010 in 121 US
communities. We examined whether 1) short-term exposure to PM2.5 increases the risk of hospitalization for
diabetes or neurological disorders, and 2) the association between short-term exposure to PM2.5 and all-cause
mortality is modified by having a previous hospitalization of diabetes or neurological disorders.
Results: We found that short term exposure to PM2.5 is significantly associated with an increase in hospitalization
risks for diabetes (1.14% increase, 95% CI: 0.56, 1.73 for a 10 μg/m
3 increase in the 2 days average), and for
Parkinson’s disease (3.23%, 1.08, 5.43); we also found an increase in all-cause mortality risks (0.64%, 95% CI: 0.42,
0.85), but we didn’t find that hospitalization for diabetes and neurodegenerative diseases modifies the association
between short term exposure to PM2.5 and all-cause mortality.
Conclusion: We found that short-term exposure to fine particles increased the risk of hospitalizations for Parkinson’s
disease and diabetes, and of all-cause mortality. While the association between short term exposure to PM2.5 and
mortality was higher among Medicare enrollees that had a previous admission for diabetes and neurological
disorders than among Medicare enrollees that did not had a prior admission for these diseases, the effect
modification was not statistically significant. We believe that these results provide useful insights regarding the
mechanisms by which particles may affect the brain. A better understanding of the mechanisms will enable the
development of new strategies to protect individuals at risk and to reduce detrimental effects of air pollution on
the nervous system.
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There is clear evidence that long- and short-term expo-
sures to particulate air pollution are associated with both
acute and chronic mortality risk; multi-site studies have
shown that ambient particulate pollution is associated
with increased risk of deaths or hospitalizations for broadly
defined cardiovascular disease [1-9]. Several studies have
also reported associations between short-term particulate
matter (PM2.5) exposure and cerebrovascular disease and
stroke [10-15]. Two studies examined the association
between pollution and mortality [16] or admission [12]
separately by stroke type and found that pollution was as-
sociated with ischemic but not hemorrhagic stroke.
The mechanisms responsible for the effects of pollution
on cerebrovascular disease and stroke are not fully under-
stood, but could be mediated through a combination of
autonomic, hemostatic, inflammatory, and vascular endo-
thelial disturbances with consequent changes in cardiac
and vascular function. For example some studies have
suggested that particulate air matter with aerodynamic
diameter less than 2.5 μg( P M 2.5) may be associated with
increased blood pressure, increased peripheral vascular
resistance, decreased brachial artery diameter, and de-
creased brachial artery flow–mediated dilation [17-23].
Other studies found that PM2.5 m a yb ea s s o c i a t e dw i t h
increased C-reactive protein [24,25]. PM2.5 and its com-
ponents have also been shown to increase oxidative
stress, [24,26-28] to decrease plaque stability [29,30],
and to increase atherosclerosis [31]. Derangements in
cerebral vascular function have been associated with stroke
incidence, as well as cognitive impairment, dementia, and
depression. Vascular oxidative stress and inflammation are
key pathogenic factors in neurovascular dysfunction [32].
The endothelial dysfunction induced by oxidative stress
can release vascular endothelial growth factor and prosta-
noids, which promote vascular leakage, protein extravasa-
tion, and cytokine production [32].
Given the documented associations between exposure
to ambient particulate air pollution and cerebrovascular
events, peripheral vascular function, cerebral vascular func-
tion [33,34], but also oxidative stress and inflammation, we
can hypothesize that PM2.5 may also affect neurological
disorders such as dementia, Alzheimer’s and Parkinson’s.
Air pollution exposure has been hypothesized to increased
inflammation in the brain [35], and brain inflammation has
been implicated in the development of Alzheimer’sd i s e a s e
(AD) [36]. Therefore the same biological responses thought
to effect cardiovascular disease through air pollution-
mediated systemic oxidative stress and inflammation
could also be relevant for diabetes and neurodegenera-
tive diseases [15,37].
Two recent studies have reported associations of traffic
with lower cognitive function in elderly men [38] and with
older women in the Nurses’ Health Study [39]. Several
epidemiological studies have shown that people with dia-
betes are vulnerable to cardiovascular health effects asso-
ciated with exposure to particle air pollution [20,40-43].
People with diabetes are at greater risk for acute environ-
mental perturbations of vascular function because of
chronic endothelial dysfunction, autonomic dysregulation,
atherosclerosis, or dysregulation of fluid balance and the
renin-angiotensin system [44,45]. Hence neurological dis-
orders and diabetes are plausible targets for PM2.5.
The elderly represent a particularly susceptible popula-
tion, and the growth in the number and proportion of
older adults in the United States is unprecedented. Dia-
betes, cognitive decline, Parkinson’s disease, dementia, and
Alzheimer's disease are also a growing burden. Alzheimer’s
disease is the most common cause of dementia among
older people. Estimates vary, but experts suggest that as
many as 5.1 million Americans may have AD, while in
2006 there were 26.6 million cases worldwide. Dementia is
the loss of cognitive functioning and memory, vascular de-
mentia is due to many small strokes. Alzheimer’sd i s e a s e
(AD) is an irreversible, progressive brain disease that slowly
destroys memory, thinking, and behavior. Parkinson's
disease is a disorder of the brain that leads to shaking
(tremors) and difficulty with walking, movement, and co-
ordination; it can occur when the nerve cells in the brain
that make dopamine are slowly destroyed, resulting in im-
pairment of muscular control by that neurotransmitter.
Parkinson's disease has also been related to autonomic dys-
function. Multiple sclerosis (MS) is an autoimmune disease
that affects the brain and spinal cord, and it is caused by
nerve damage which in turn can be caused by inflamma-
tion. For at least 20 years, diabetes rates in North America
have been increasing substantially. The increasing preva-
lence of diabetes makes this susceptibility factor especially
important to study.
The hypotheses of this study are: 1) short term expos-
ure to PM2.5 might be associated with an increased risk
of hospitalizations for diabetes or neurological disorders
in the elderly; and 2) elderly with diabetes or neurological
disorders may have higher risk of deaths from short term
exposure to PM2.5 compared to elderly without these con-
ditions. Thus, the purpose of this investigation is twofold:
we will estimate the effect of short-term exposure of PM2.5
on 1) hospitalizations for neurological disorders and
diabetes, and 2) on all-cause mortality in all Medicare
deaths. Importantly we will also assess whether the mor-
tality risks associated with PM2.5 among the elderly are
modified by a previous hospital admission for a neuro-
logical disorder or diabetes.
To achieve these aims we will conduct a multi-site
case-crossover study, where for each county, we esti-
mate: 1) the short-term effects of PM2.5 on hospitaliza-
tions for neurological disorders and diabetes; 2) the
short-term effects of PM2.5 on all-cause mortality; 3) and
Zanobetti et al. Environmental Health 2014, 13:38 Page 2 of 11
http://www.ehjournal.net/content/13/1/38the short-term effects of PM2.5 on all-cause mortality in
a susceptible population defined as persons 65 or older
with at least one Medicare covered hospital admission
for diabetes or neurological disorders.
Methods
Health data
We used the Medicare beneficiary denominator file from
the Centers for Medicare and Medicaid services (CMS)
to identify beneficiaries who were enrolled in the Medi-
care fee-for-service (FFS) plan between 1999 and 2010.
The denominator file contains information on beneficiar-
ies’ eligibility and enrollment in Medicare and the date of
death was cross-referenced with the Social Security
Administration's Master Beneficiary Record [46].
From the initial denominator file we excluded benefi-
ciaries with age <65 years, those enrolled in managed-
care programs over an entire year, and those who re-
sided outside of the targeted counties. We identified all
deaths by selecting those subjects who died among all
Medicare enrollees denominator file.
We linked the person-years beneficiary data with the
Medicare Provider Analysis and Review (MEDPAR) in-
patient data to identify all Medicare FFS patients who
were hospitalized for the targeted medical conditions.
The MEDPAR inpatient data includes information on
patient demographics (age, sex, race), dates of admission
and discharge, admission sources and types, principal
and secondary diagnosis codes, and procedure codes, de-
fined by the International Classification of Diseases, Ninth
Revision, (ICD-9).
We used the Medicare claims records from the Medi-
care Provider Analysis and Review (MEDPAR) file to se-
lect only emergency admissions, and to identify previous
cause of hospital admissions, based on primary and sec-
ondary diagnosis codes of all hospitalizations for any
causes up to one year prior to the initial condition-
specific hospitalization. Because diabetes and neuro-
logical disorders might not be the primary reason for an
admission, individuals for whom the condition was
noted as the primary admission cause or as any of nine
coexisting conditions were classified as having the con-
dition for the mortality analysis. We excluded patients
who could not be merged with the Medicare denomin-
ator file.
The medical conditions that we examined were: diabetes
(ICD-9: 250), dementia (ICD-9: 290), Alzheimer's disease
(ICD-9: 331.0), Parkinson's disease (ICD-9: 332), and mul-
tiple sclerosis (ICD-9: 340). The primary code of admis-
sion reflects the main cause of admissions and therefore
we used only primary emergency admissions to study the
effect of PM2.5 on hospitalization.
The research was approved by the institutional review
boards (IRB) of the Harvard School of Public Health.
Environmental data
We obtained particulate air matter with aerodynamic
diameter less than 2.5 μg( P M 2.5)d a t af r o mU SE n v i r o n -
mental Protection Agency’s Air Quality System Technology
Transfer Network (U.S. EPATechnology Transfer Network,
2005) which provide daily PM2.5 concentrations from the
U.S. EPA’s National and State Local Ambient Monitoring
stations (NAMS and SLAMS).
For most cities, the metropolitan county encompassed
the city and much of its suburbs; therefore we aggre-
gated counties where the city’s population extends be-
yond the boundaries of one county; henceforth we refer
to the analyzed geographical areas as “community”.
Given that PM2.5 is not available daily in every city, to
be included in our study, we required that at least 219
(60% of days) days of data in at least one year be avail-
able in each community. With this criterion, we selected
121 communities (180 counties) across the US for the
years 1999–2010, based on the availability of air pollu-
tion, and representing a geographic distribution across
the country.
Many of the communities have more than one moni-
toring location, requiring a method to average over mul-
tiple locations. Therefore we computed the community
daily mean PM2.5 concentrations using an algorithm pre-
viously described [47,48] that accounts for the different
monitor-specific means and variances.
We defined our exposure as the 2 days average of PM2.5,
that is, the average of the same (lag 0) and previous (lag 1)
day. We present the results as percent change in mortality
(or cause specific hospital admission) for 10 μg/m
3 in-
crease in the two days average of PM2.5.
We obtained local meteorological data from the Na-
tional Oceanic and Atmospheric Administration (NOAA),
including daily temperature (mean, min, max), daily dew
point, date, and weather station.
Analytical strategy
To estimate the short-term effects of PM2.5 on hospitali-
zations for neurological disorders and diabetes, and to
determine whether the mortality risks associated with
short-term PM2.5 among elderly is exacerbated by a
previous hospital admission for neurological disorders
or diabetes, we conducted a community specific case-
crossover analysis.
We created indicator variables denoting whether or not
an individual had a primary or secondary hospitalization
for diabetes or neurological disorder at any time before
death. In the model having as outcome all-cause deaths,
we also examined effect modification by specific cause of
prior admission by including an interaction terms between
PM2.5 and these indicator variables in the same model.
The case-crossover design was developed as a variant of
the case–control design to study the effects of transient
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cases and compares each subject’s exposure experience in
a time period just prior to a case-defining event with that
subject’s exposure at other times. Since there is perfect
matching on all measured or unmeasured subject charac-
teristics that do not vary over time there can be no con-
founding by those characteristics.
Bateson and Schwartz [50,51] demonstrated that by
choosing control days close to event days, even very
strong confounding of exposure by seasonal patterns
could be controlled by design in the case control ap-
proach. This makes the approach an attractive alterna-
tive to the Poisson models for time series analysis.
We applied the time-stratified case-crossover design, and
we defined the case as the day of death (or hospitalization);
we then chose control days as every third day in the same
month and year as the case.
The analysis was conducted for the hospitalization
data and for the mortality data for each community sep-
arately, and we applied a conditional logistic regression
controlling for day of the week and weather. To control
for the potential confounding by weather, we included
into the regression model average temperature for the
same and previous day. Since risk may vary nonlinearly
with temperature, we used a regression spline (with 3
degrees of freedom) both for the same and previous day.
The effect of PM2.5 on hospitalization and mortality was
modeled linearly.
Case-crossover analyses lend themselves to the analysis
of effect modification. To determine whether the mortality
risks associated with short-term PM2.5 among elderly is
modified by a previous hospital admission of neurological
disorders or diabetes, we included into the same regres-
sion model interaction terms between PM2.5 and the indi-
cator variables indicating whether or not an individual
had a primary or secondary hospitalization for diabetes,
Parkinson’s disease, Alzheimer’s disease, and dementia.
To examine effect modification by sex, age (65–75, >75)
or race (black, white, other races) we ran the conditional
logistic regression stratified by each demographic charac-
teristic. To compare the differences between the risk esti-
mates in two categories of a potential effect modifier (e.g.,
the difference between males and females) we computed
the 95 percent confidence interval as: ^ Q1−^ Q2
  
  1:96
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
^ SE2
1 þ ^ SE2
2
q
where and ^ Q1 and ^ Q2 are the estimates for
the two categories (e.g., males and females), and ^ SE1 and
^ SE2 are their respective standard errors. We reject the null
hypothesis that the group means are the same if the inter-
val does not contain zero [52].
In a second stage of the analysis, the community spe-
cific results of the first stage analyses were combined
using the multivariate meta-analysis technique of Berkey
and coworkers [53]. To be conservative we report the
results incorporating a random effect, whether or not
there was a significant heterogeneity.
Results
From the Medicare beneficiary denominator file we se-
lected 6,982,678 deaths among all Medicare enrollees
during the period 1999 to 2010 in 121 US communi-
t i e s .F r o mt h eM e d i c a r ed a t aw es e l e c t e dt h es u b j e c t s
65 and older who were hospitalized for the targeted
medical conditions.
Table 1 shows the descriptive statistics for the counts
of deaths, counts of previous cause-specific hospitalization
among those who died; and the number of cause-specific
hospital admissions summarized across the 121 communi-
ties. Among the subjects who died during the study period
(approximately 7 million) in all the communities, 13.7%,
3.8%, and 3.3% of subjects had a previous hospitalization
noting as a cause or a comorbid condition diabetes, Alz-
heimer’s disease, and dementia respectively. Parkinson's
disease and multiple sclerosis represent a lower propor-
tion of persons with this specific admission. The primary
emergency cause-specific hospitalizations in the same
table follow the same pattern, with the higher number of
hospitalizations for diabetes, and Alzheimer’s disease, and
very few primary admissions for multiple sclerosis.
Figure 1 shows the location of the 121 US communi-
ties included in the study; the symbol size represent the
population in each community, while the color represent
the average PM2.5 concentrations during the entire study
period. High levels of PM2.5 (red) are in California and
in the industrial Midwest.
Additional file 1: Table S1 presents for each of the 121
communities the daily mean concentration levels for
PM2.5, and of temperature; the total number of deaths
and total number of previous admissions before death
for dementia, Alzheimer’s disease, Parkinson’s disease,
multiple sclerosis and diabetes. Additional file 1: Table S2
shows the counts of primary emergency cause-specific
hospitalizations. Due to the small number of primary ad-
mission for multiple sclerosis we excluded these from the
hospitalization analysis.
Table 2 presents the results of the analyses for 1) all-
cause mortality and 2) primary cause-specific hospital
admissions. We found a 0.64% increase (95% CI: 0.42,
0.85) in all-cause mortality for each 10 μg/m
3 increase in
the two days average of PM2.5 among all Medicare par-
ticipants. We also found 0.60% increase (95% CI: 0.36,
0.84) in all-cause mortality among persons who had
never been hospitalized for the specified conditions dur-
ing the study period. We also found a significant, and
larger, association between short-term exposure to PM2.5
and all-cause mortality in subjects with previous hospital
admissions for diabetes (0.76%; 0.39, 1.12), Parkinson’s
disease (1.15%; 0.09, 2.23), dementia (0.94%; 0.01, 1.89),
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differences were not statistically significant.
Table 2 summarizes also the results for cause-specific
hospital admissions. For each 10 μg/m
3 increase in the
two days average of PM2.5 we found statistically signifi-
cant increases in hospital admissions for Parkinson’s dis-
ease (3.23%; 95% CI: 1.08, 5.43), and diabetes (1.14%;
95% CI: 0.56, 1.73). The results for the other admissions
causes are positive but non-significant due to the small
number of cases in some cities, hence large confidence
intervals in the meta-analysis.
When the analysis was stratified by sex, race and age
group we did not find significant evidence of effect
modification by any of the demographic characteristics
in the mortality analysis (Figure 2). In the hospital ad-
missions analysis (Figure 3) instead we found that age
was a significant modifier (P-value=0.009) in Alzheimer’s
disease with a 3.48% (95% CI: 0.83, 6.19) increase in
Table 1 Counts of deaths among Medicare enrollees; counts of cause-specific admission prior to death; and counts of
cause-specific primary emergency hospitalizations, summarized over the 121 cities
Minimum 1st Quartile Mean 3rd Quartile Maximum Total %
Deaths 1,710 13,342 57,708 61,409 444,791 6,982,678
Previous cause-specific hospitalization among deaths:
Dementia 22 323 1,910 1,828 26,087 231,091 3.3
Alzheimer's disease 32 503 2,192 2,510 16,908 265,219 3.8
Parkinson’s disease 11 175 814 872 7,592 98,470 1.4
Multiple sclerosis 1 14 61 61 671 7,337 0.1
Diabetes 184 1,822 7,897 9,442 71,186 955,547 13.7
Cause-specific hospitalizations:
Dementia 6 107 736 709 8,944 89,082
Alzheimer's disease 10 252 1,208 1,530 9,846 146,172
Parkinson’s disease 4 63 335 342 4,430 40,496
Multiple sclerosis 0 7 38 38 563 4,634
Diabetes 90 834 3,658 4,079 53,485 442,622
Figure 1 Map of the US with the location of the 121 communities; the symbol size represent the population in each community, while
the color represent the average PM2.5 in the community.
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to a −0.27% (95% CI: −1.59, 1.06) increase in hospitaliza-
tions in subjects with over 75 years of age. The results by
race are very unstable due to the distribution by race and
cause of admissions.
Because of our novel association between PM2.5 and
admissions for neurological disorders, we also examined
the effect of up to 3 previous days (lags 0, 1, 2) and the
cumulative effect expressed by the moving average of
PM2.5 up to 6 previous days (moving average from 2 days
(01) up to 6 days (05)) (Figure 4). We found that the ef-
fects are immediate at lag 0 and persist for 2 or 3 days
averages of PM2.5.
Discussion
Most early attention to the association of particles with
hospitalization and mortality has focused on heart and
lung disease; lately interest has shifted to cerebrovascular
disease, stroke, and cognitive impairment. In this multi-
city study we found that short term exposure to fine
particles increase the risk of all-cause mortality and of
hospitalizations for diabetes and neurological disorders.
This is the first study to examine susceptible popula-
tion defined as those elderly with a hospitalization for
dementia, Alzheimer’s disease, Parkinson’s disease, and
multiple sclerosis.
We found significant effects of PM2.5 on hospitalization
for Parkinson’s disease and diabetes; and in subjects aged
65–75 with Alzheimer’s disease. We also found that short
term exposure to fine particles increased mortality risk in
subjects with previous admissions for diabetes, Parkinson’s
disease, dementia, and Alzheimer’s disease. While those
risks were not significantly higher than the mortality risk
associated with short-term effect of PM2.5 among then
Medicare enrollees that were never hospitalized for any of
Table 2 Percent increase for 10 μg/m
3 increase in the two
days average PM2.5: Combined across the 121
communities
% 95% CI
1) Mortality
All deaths 0.64 0.42 0.85
Deaths without medical conditions 0.60 0.36 0.84
Mortality by previous cause of hospitalization
Alzheimer's disease 1.04 0.36 1.72
Dementia 0.94 0.01 1.89
Parkinson's disease 1.15 0.09 2.23
Multiple Sclerosis 4.01 -0.03 8.21
Diabetes 0.76 0.39 1.12
2) Cause specific hospitalizations
Alzheimer's disease 0.20 -1.26 1.69
Dementia 0.92 -0.44 2.30
Parkinson's disease 3.23 1.08 5.43
Diabetes 1.14 0.56 1.73
1) Total Mortality in all Medicare Deaths and in subjects with previous cause-
specific hospital admissions.
2) Cause-specific Primary Emergency Hospitalizations.
Figure 2 Percent increase in total mortality for 10 μg/m
3 increase in the two days average PM2.5 for all Medicare deaths and
separately by specific previous cause of admission and by demographics characteristics. The results are combined across the
121 communities.
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The lack of significant effect modification of the mortality
risk by pre-existing neurological disease could be due to
limitation in the data used. More specifically, Medicare
data only report hospitalization by cause and therefore we
are not capturing enrollees with dementia or neurological
disorder who are not hospitalized.
While this study focus on the mortality and hospitaliza-
tions of adults over the age of 65 with a specific admission
for neurological disorder, previous studies have reported
direct effects of particles on neurological outcomes in-
cluding cognitive function. This suggests common path-
ways, which may explain the associations we saw.
In Germany elderly women were tested for mild cogni-
tive impairment and the authors found that chronic ex-
posure to traffic-related PM2.5 may be involved in the
pathogenesis of Alzheimer’s disease [54]. Power and co-
authors found that exposure to black carbon, a marker
Figure 3 Percent increase in cause specific primary emergency hospital admissions for 10 μg/m
3 increase in the two days average
PM2.5 separately by specific cause of admission and by demographics characteristics. The results are combined across the
121 communities.
Figure 4 Percent increase in cause specific primary emergency hospital admissions for 10 μg/m
3 increase in PM2.5 for lags 0, 1, 2 and
moving average from 2 days (01) up to 6 days (05). The results are combined across the 121 communities.
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nitive function in older men [38]. In the Chinese Longitu-
dinal Healthy Longevity Survey, the authors found that air
pollution, measured by an index of particulate and gas
concentrations, increased the odds of disability in activ-
ities of daily living, cognitive impairment, and health defi-
cits [55]. Finally in a study of older women higher levels of
long term exposure to PM2.5 and coarse particles were as-
sociated with significantly faster cognitive decline [56].
Air pollution can produce its adverse effects in the
central nervous system (CNS), through a variety of cellu-
lar and molecular mechanisms [57]. Some hypotheses
have been suggested to explain these observed associa-
tions. One hypothesis is that the presence of particles in
the brain due to the migration of particles from the nose
to the brain, can causes neurological disorders. An alter-
native hypothesis is that ambient particle inhalation has
a primary effect on the vasculature in the central ner-
vous system (CNS), resulting in subsequent impairment.
Particles have been shown to translocate from the nose
up the olfactory nerve into the brain, including the stri-
atum frontal cortex, and cerebellum [58,59]. This in turn
is associated with increased brain inflammatory responses
[35,60] and changes in neurotransmitter levels [61]. In
humans, diesel exhaust exposure has been shown to alter
EEG responses, with patterns indicative of cortical stress
[62]. In polluted areas of Mexico City, dogs had more pre-
frontal lesions, neuro-inflammation, gliosis, and particle
deposition. In these polluted areas, brain MRI’s of chil-
dren had more prefrontal lesions; autopsy studies of ac-
cident victims showed upregulation of cyclooxygenase-2
and CD14 [63-65].
Wellenius and co-authors [33] evaluated the association
between PM2.5 and cerebrovascular hemodynamics in a
cohort of older adults. The authors found that exposure to
PM2.5 was associated with higher resting cerebrovascular
resistance and lower cerebral blood flow velocity, suggest-
ing that alterations in cerebrovascular hemodynamics may
underlie the increased risk of particle-related acute cere-
brovascular events.
Another component of vascular function is arterial
stiffness; stiffening of the arteries is a process associated
with aging and cardiovascular risk factors. In a recent
paper Metha and co-authors [34], in a cohort of elderly
men in the Boston area, found that short-term changes
in air pollution were associated with augmentation index
and augmentation pressure, correlates of arterial stiff-
ness, supporting the hypothesis that exposure to air pol-
lution may affect vascular function.
Therefore emerging evidence also suggests that possible
biological mechanisms through which pollution can affect
neurological disease are air pollution-induced neuro in-
flammation, oxidative stress, cerebrovascular dysfunction,
and systemic inflammation. A better understanding of the
mechanisms will enable the development of new strategies
to protect individuals at risk and to reduce detrimental ef-
fects of air pollution on the nervous system and mental
health [32,57].
We also found a significant PM2.5 effect in subjects
with primary hospitalization for diabetes and in subjects
with a previous admission for diabetes, which is higher
(although not statistically significantly higher) than the
mortality risk in subjects without any of the specified
pre-existing conditions. Previous epidemiological studies
suggested that people with a hospitalization for diabetes
are vulnerable to cardiovascular health effects associated
with exposure to particle air pollution. In a 2002 study
of 4 US communities we found that diabetics have double
the risk of a PM10-associated cardiovascular admission
compared with non-diabetics [40]. Similarly, we estimated
a 2.0-fold higher mortality risk associated with PM10
exposure for diabetics than for controls in a 2004 case-
crossover study [41]. Likewise, PM10 effects on mortality
were stronger in diabetics than in non-diabetics in 9
Italian communities [42]. O’Neill and co-authors in two
studies examined Boston residents with type 2 diabetes. In
one of the study [43] the authors found a positive associ-
ation between air pollution and inflammatory markers as
ICAM-1, VCAM-1 and vWF, suggesting that inflamma-
tory mechanisms may explain the increased risk of air
pollution-associated cardiovascular events among persons
with diabetes. In the other study the authors found associ-
ations between air pollution and endothelium-dependent
and -independent vascular reactivity measures [20]. Our
results are not directly comparable to these previously
published, but we also found increased mortality and hos-
pitalizations risks in diabetics.
Similarly, studies have shown that air pollution is cap-
able of causing these same physiological responses [15,37].
Some studies have suggested that PM may be associated
with reduced heart rate variability [66-70], and increased
C-reactive protein [24,25]. PM2.5 and PM2.5 components
have also been shown to increase oxidative stress, includ-
ing in the heart [24,26-28], to decrease plaque stability
[29,30], and to increase atherosclerosis [31]. Therefore it
is plausible for air pollution to be a factor in developing
diabetes [71].
Among the limitations of the study, we measure “sus-
ceptibility” by a previous hospitalization as one of the
diagnosis in a list of diseases. However, this clearly re-
sults in misclassification of the effect modifier, as people
in our study population may have diabetes or dementia
without a previous admission, or without it being noted
in that admission. We also do not include Medicare par-
ticipants in managed care because their care is paid for
by capitation, and hence no specific events are reported
to Medicare. This may limit generalization of these
results. Another limitation though is due to Medicare
Zanobetti et al. Environmental Health 2014, 13:38 Page 8 of 11
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Conclusions
In this multi-city study we found that short-term exposure
to fine particles increased the risk of hospitalizations for
Parkinson’s disease and diabetes and of all-cause mortality
in Medicare enrollees. The associations persist in the mor-
tality risk of subpopulations of Medicare patients with
neurological disease and diabetes hospitalizations prior to
death, even though these are not significantly different
than the mortality risk among then Medicare enrollees
that were never hospitalized for any of these diseases.
The same biological responses thought to effect cardio-
vascular disease through air pollution-mediated systemic
oxidative stress, inflammation, and cerebrovascular dys-
function could also be relevant for diabetes and neurode-
generative diseases. Therefore these results give additional
insight into the mechanisms by which particles may affect
the brain. More studies are needed to understand the
association between exposure and the risk of neurode-
generative diseases development, in order to develop
preventative strategies, and improve air quality to reduce
the burden of neurological morbidity and mortality.
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